Cornerstone Pharmaceuticals Inc., of Cranbury, N.J., said that, following a successful end-of-phase I type B meetings with the FDA, the company has a clear clinical and regulatory path forward to conduct pivotal trials of its lead compound, CPI-613, in patients with acute myeloid leukemia (AML) and pancreatic cancer.